The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating... Diabetologia (2017) 60:1801–1812 DOI 10.1007/s00125-017-4330-3 ARTICLE The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype 1 1,2,3 1 1 Ángela Vinué & Jorge Navarro & Andrea Herrero-Cervera & Marta García-Cubas & 1 1,4,5 1,4,5 Irene Andrés-Blasco & Sergio Martínez-Hervás & José T. Real & 1,4,5 1,5 Juan F. Ascaso & Herminia González-Navarro Received: 25 January 2017 /Accepted: 10 May 2017 /Published online: 12 June 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract blood pressure but this was independent of body weight loss. Aims/hypothesis Recent clinical studies indicate that Both drugs significantly decreasedatheromaplaquesize. glucagon-like peptide-1 (GLP-1) analogues prevent acute car- Compared with vehicle-treated control mice, lixisenatide diovascular events in type 2 diabetes mellitus but their mech- treatment generated more stable atheromas, with fewer in- anisms remain unknown. In the present study, the impact of flammatory infiltrates, reduced necrotic cores and thicker fi- GLP-1 analogues and their potential underlying molecular brous caps. Lixisenatide-treated mice also displayed dimin- high mechanisms in insulin resistance and atherosclerosis are ished IL-6 levels, proinflammatory Ly6C monocytes and investigated. activated T cells. In vitro analysis showed that, in macro- −/− +/− Methods Atherosclerosis development was evaluated in phages from Apoe Irs2 mice, lixisenatide reduced the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetologia Springer Journals

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype

Loading next page...
 
/lp/springer_journal/the-glp-1-analogue-lixisenatide-decreases-atherosclerosis-in-insulin-FZeMYuUREJ
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Internal Medicine; Metabolic Diseases; Human Physiology
ISSN
0012-186X
eISSN
1432-0428
D.O.I.
10.1007/s00125-017-4330-3
Publisher site
See Article on Publisher Site

Abstract

Diabetologia (2017) 60:1801–1812 DOI 10.1007/s00125-017-4330-3 ARTICLE The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype 1 1,2,3 1 1 Ángela Vinué & Jorge Navarro & Andrea Herrero-Cervera & Marta García-Cubas & 1 1,4,5 1,4,5 Irene Andrés-Blasco & Sergio Martínez-Hervás & José T. Real & 1,4,5 1,5 Juan F. Ascaso & Herminia González-Navarro Received: 25 January 2017 /Accepted: 10 May 2017 /Published online: 12 June 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract blood pressure but this was independent of body weight loss. Aims/hypothesis Recent clinical studies indicate that Both drugs significantly decreasedatheromaplaquesize. glucagon-like peptide-1 (GLP-1) analogues prevent acute car- Compared with vehicle-treated control mice, lixisenatide diovascular events in type 2 diabetes mellitus but their mech- treatment generated more stable atheromas, with fewer in- anisms remain unknown. In the present study, the impact of flammatory infiltrates, reduced necrotic cores and thicker fi- GLP-1 analogues and their potential underlying molecular brous caps. Lixisenatide-treated mice also displayed dimin- high mechanisms in insulin resistance and atherosclerosis are ished IL-6 levels, proinflammatory Ly6C monocytes and investigated. activated T cells. In vitro analysis showed that, in macro- −/− +/− Methods Atherosclerosis development was evaluated in phages from Apoe Irs2 mice, lixisenatide reduced the

Journal

DiabetologiaSpringer Journals

Published: Jun 12, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off